Page last updated: 2024-11-13

g007-lk

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67960134
CHEMBL ID2325503
SCHEMBL ID9904844
SCHEMBL ID9904845
MeSH IDM0586310

Synonyms (29)

Synonym
4-{5-[(e)-2-{4-(2-chlorophenyl)-5-[5-(methylsulfonyl)pyridin-2-yl]-4h-1,2,4-triazol-3-yl}ethenyl]-1,3,4-oxadiazol-2-yl}benzonitrile
1ak ,
bdbm50427989
4HYF
S7239
CHEMBL2325503 ,
(e)-4-(5-(2-(4-(2-chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4h-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)benzonitrile
HIWVLHPKZNBSBE-OUKQBFOZSA-N ,
SCHEMBL9904844
SCHEMBL9904845
1380672-07-0
g007-lk
AC-33045
1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-({trans-4-[(dimethylamino)methyl]cyclohexyl}amino)-1,5-naphthyridin-3-yl]ethanone hydrochlorid e (1:1)
J-690154
EX-A656
AKOS030526468
benzonitrile, 4-[5-[(1e)-2-[4-(2-chlorophenyl)-5-[5-(methylsulfonyl)-2-pyridinyl]-4h-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]-
A1-02247
NCGC00390587-01
4-[5-[(e)-2-[4-(2-chlorophenyl)-5-(5-methylsulfonylpyridin-2-yl)-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl]benzonitrile
4-{5-[(1e)-2-[4-(2-chlorophenyl)-5-(5-methanesulfonylpyridin-2-yl)-4h-1,2,4-triazol-3-yl]ethenyl]-1,3,4-oxadiazol-2-yl}benzonitrile
AS-75199
CCG-269912
Q27451850
A900891
(e)-4-(5-(2-(4-(2-chlorophenyl)-5-(5-(methylsulfonyl)pyridin-2-yl)-4h-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)benzonitrile;g007-lk
g-007-lk
NCGC00390587-03

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Poly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)IC50 (µMol)0.03430.00190.62935.0000AID1548004; AID1548006; AID1548007; AID1589482; AID1589485; AID1589501; AID728459; AID728592
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.00450.00011.774010.0000AID1548006
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)12.52910.00011.753610.0000AID1548004; AID728455
Poly [ADP-ribose] polymerase 1Homo sapiens (human)IC50 (µMol)100.00000.00020.81239.8100AID1548032; AID1589484
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)0.05810.00002.800510.0000AID1548004
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.05810.00002.398310.0000AID1548004
Protein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)IC50 (µMol)100.00000.56234.10539.7724AID1548034; AID1589512
Poly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)IC50 (µMol)0.03860.00210.67505.1300AID1548005; AID1548006; AID1548007; AID1589483; AID1589485; AID1589501; AID728590; AID728592
Protein-serine O-palmitoleoyltransferase porcupineMus musculus (house mouse)IC50 (µMol)0.02500.00040.00680.0250AID728590
Poly [ADP-ribose] polymerase 2Homo sapiens (human)IC50 (µMol)100.00000.00010.21886.6000AID1548033; AID1589511
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
peptidyl-serine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
peptidyl-threonine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle organizationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mRNA transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
spindle assemblyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cell divisionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomerase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomeric DNA bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of maintenance of mitotic sister chromatid cohesion, telomericPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrion organizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA metabolic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of protein localizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to oxidative stressPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein modification processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrial DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
telomere maintenancePoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
apoptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to gamma radiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
carbohydrate biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein autoprocessingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
macrophage differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of DNA-templated transcription, elongationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to insulin stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of transcription elongation by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to UVPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of innate immune responsePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase 1Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of catalytic activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of mitochondrial depolarizationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of SMAD protein signal transductionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of necroptotic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein localization to chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to zinc ionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
replication fork reversalPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of cGAS/STING signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of protein localization to nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of single strand break repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
response to aldosteronePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of adipose tissue developmentPoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to amyloid-betaPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of myofibroblast differentiationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
regulation of base-excision repairPoly [ADP-ribose] polymerase 1Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cellular response to nerve growth factor stimulusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ATP generation from poly-ADP-D-ribosePoly [ADP-ribose] polymerase 1Homo sapiens (human)
negative regulation of ATP biosynthetic processPoly [ADP-ribose] polymerase 1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
chromatin organizationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of gene expressionProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
viral protein processingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
translesion synthesisProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of DNA-templated transcriptionProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of fibroblast proliferationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein poly-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein auto-ADP-ribosylationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
negative regulation of protein K63-linked ubiquitinationProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
DNA repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
base-excision repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA damage responsePoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
decidualizationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
positive regulation of cell growth involved in cardiac muscle cell developmentPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
response to oxygen-glucose deprivationPoly [ADP-ribose] polymerase 2Homo sapiens (human)
extrinsic apoptotic signaling pathwayPoly [ADP-ribose] polymerase 2Homo sapiens (human)
hippocampal neuron apoptotic processPoly [ADP-ribose] polymerase 2Homo sapiens (human)
DNA repair-dependent chromatin remodelingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
double-strand break repairPoly [ADP-ribose] polymerase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (71)

Processvia Protein(s)Taxonomy
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
histone bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatin bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein kinase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear estrogen receptor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
ubiquitin protein ligase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
identical protein bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein homodimerization activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
histone deacetylase bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
R-SMAD bindingPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator activator activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-tyrosine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein-histidine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BS6 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H3S10 serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-histone H2BE35 glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
protein bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleotidyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
K63-linked polyubiquitin modification-dependent protein bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
DNA-binding transcription factor bindingProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+- protein-lysine ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
transcription corepressor activityProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
metal ion bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
O-acyltransferase activityProtein-serine O-palmitoleoyltransferase porcupineMus musculus (house mouse)
chromatin bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
damaged DNA bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleosome bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
poly-ADP-D-ribose bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD DNA ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein-serine ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+- protein-aspartate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein-glutamate ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
poly-ADP-D-ribose modification-dependent protein bindingPoly [ADP-ribose] polymerase 2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
Golgi membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Golgi apparatusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle polePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear porePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear replication forkPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
mitochondrionPoly [ADP-ribose] polymerase 1Homo sapiens (human)
membranePoly [ADP-ribose] polymerase 1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of double-strand breakPoly [ADP-ribose] polymerase 1Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 1Homo sapiens (human)
chromatinPoly [ADP-ribose] polymerase 1Homo sapiens (human)
transcription regulator complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-containing complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
protein-DNA complexPoly [ADP-ribose] polymerase 1Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleolusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
Golgi apparatusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytosolProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
cytoplasmProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
nucleusProtein mono-ADP-ribosyltransferase PARP10Homo sapiens (human)
Golgi membranePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
perinuclear region of cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
endoplasmic reticulum membraneProtein-serine O-palmitoleoyltransferase porcupineMus musculus (house mouse)
site of DNA damagePoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
site of DNA damagePoly [ADP-ribose] polymerase 2Homo sapiens (human)
nucleolusPoly [ADP-ribose] polymerase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (135)

Assay IDTitleYearJournalArticle
AID728557Apparent volume of distribution in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728468Oral bioavailability in male ICR mouse measured from AUC (0 to t) at 5 mg/kg2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589516Inhibition of TNKS/TNKS2-mediated beta-catenin signaling in human COLO320DM cells assessed as down regulation of AXIN2 mRNA expression at 0.1 to 1 uM measured after 48 hrs by RT-PCR analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589499Inhibition of TNKS/TNKS2 in human COLO320DM cells assessed as upregulation of AXIN2 expression at 0.1 uM measured after 16 hrs by Western blot analysis relative to G007-LK2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728459Inhibition of TNSK1 (unknown origin) by NAD+-dependent autopoly(ADP ribosyl)lation assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728565AUC (0 to infinity) in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589495Antiproliferative activity against human RKO cells assessed inhibition of cell growth measured after 5 days by MTT assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728567AUC (0 to t) in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589501Inhibition of TNKS/TNKS2 (unknown origin) expressed in HEK293 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728585Half life in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728564AUC (0 to infinity) in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589511Inhibition of human recombinant N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELIS2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1548004Inhibition of recombinant human N-terminal TEV cleavage site-fused/FLAG-poly his-tagged TNKS SAM-PARP domain (1024 to 1327 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation preincubated for 10 mins followed by biotinylated-N2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589503Half life in Sprague-Dawley rat at 1 mg/kg, iv2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589512Inhibition of human recombinant N-terminal TEV-cleavgae site-fused-FLAG/Polyhis-tagged PARP10 (2 to 583 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of bioti2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589493Stability in mouse liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728573Cmax in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548032Inhibition of recombinant human PARP1 expressed in Escherichia coli assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELISA2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728562AUC (0 to infinity) in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728462Bioavailability in male ICR mouse measured from AUC (0 to infinity) at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728555Mean residence time (0 to infinity) in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548033Inhibition of human recombinant N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 cells assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELIS2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728464Oral bioavailability in male ICR mouse measured from AUC (0 to infinity) at 5 mg/kg2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589508Tmax in Sprague-Dawley rat at 3 mg/kg, po2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728463Oral bioavailability in female ICR mouse measured from AUC (0 to infinity) at 5 mg/kg2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589498Efflux ratio of permeability across apical to basolateral side over basolateral to apical side in MDCK2-MDR1 cells2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728583Tmax in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589526Toxicity in mouse xenografted with human COLO320DM cells assessed as body weight loss at 40 mg/kg, ip administered twice daily for 11 days2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589520Effect on hippo signaling protein in human COLO320DM cells assessed as change in CYR61 expression at 0.1 to 1 uM measured after 48 hrs by RT-PCR analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728559Apparent volume of distribution in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548044Tmax in Sprague-Dawley rat at 3 mg/kg, po2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589492Stability in human liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728586Half life in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548007Inhibition of TNKS/TNKS2 (unknown origin) expressed in human DLD1 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589506Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1548047Half life in Sprague-Dawley rat at 1 mg/kg, iv2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589504AUC (infinity) in Sprague-Dawley rat at 1 mg/kg, iv2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589489Permeability of the compound by PAMPA2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1548018Protein binding in mouse plasma assessed as unbound fraction at 1 uM measured after 24 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548034Inhibition of human recombinant N-terminal TEV-cleavgae site-fused-FLAG/Polyhis-tagged PARP10 (2 to 583 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of bioti2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728584Half life in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728560AUC (0 to infinity) in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548010Permeability of the compound measured after 4 hrs by PAMPA2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589518Effect on hippo signaling protein in human COLO320DM cells assessed as change in AMOTL2 expression at 0.1 to 1 uM measured after 48 hrs by RT-PCR analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728470Mean residence time (0 to infinity) in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548040Dose normalized AUC (infinity) in Sprague-Dawley rat at 1 mg/kg, iv2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548037Inhibition of TNKS/TNKS2-mediated WNT/beta-catenin signaling pathway in human COLO320DM cells assessed as upregulation of AXIN2 expression at 0.1 uM measured after 16 hrs by Western blot analysis relative to control2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548036Antiproliferative activity against human RKO cells assessed inhibition of cell growth measured after 5 days by MTT assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728561AUC (0 to infinity) in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589517Inhibition of TNKS/TNKS2-mediated beta-catenin signaling in human COLO320DM cells assessed as down regulation of TCF7 mRNA expression at 0.1 to 1 uM measured after 48 hrs by RT-PCR analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589486Antiproliferative activity against human COLO320DM cells assessed as inhibition of cell growth measured after 4 days by CellTiter-Glo assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728575Cmax in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548019Efflux ratio of permeability across basolateral to apical side over apical to basolateral side in MDCK2-MDR1 cells2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728563AUC (0 to infinity) in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589502Initial plasma concentration in Sprague-Dawley rat at 1 mg/kg, iv2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589490Protein binding in human serum assessed as unbound fraction at 1 uM measured after 24 hrs by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728457Ratio of JW74 IC50 to compound IC50 for TNKS1/2 in HEK293 cells assessed as inhibition of Wnt/beta-casein pathway after 24 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728578Tmax in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548009Aqueous solubility of the compound in pH 7.4 phosphate buffer saline at 200 uM incubated for 1 hr under shaking condition by UV spectra analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589494Antiproliferative activity against human COLO320DM cells assessed inhibition of cell growth measured after 5 days by MTT assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728582Half life in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1866943Toxicity in mouse xenografted with COLO 320DM cells assessed as reduction in body weight at 60 mg/kg, po daily relative to control2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.
AID728574Cmax in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728456Ratio of JW78 IC50 to compound IC50 for TNKS2 (unknown origin) by NAD+-dependent autopoly(ADP ribosyl)lation assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728466Bioavailability in male ICR mouse measured from AUC (0 to t) at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728558Clearance in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548006Inhibition of TNKS/TNKS2 (unknown origin) expressed in HEK293 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589497Efflux ratio of permeability across apical to basolateral side over basolateral to apical side in MDCK2 cells2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728589Half life in human liver microsomes2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728458Cmax in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589507Cmax in Sprague-Dawley rat at 3 mg/kg, po2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728570AUC (0 to t) in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548043Cmax in Sprague-Dawley rat at 3 mg/kg, po2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589482Inhibition of recombinant human N-terminal TEV cleavage site-fused/FLAG-poly his-tagged TNKS SAM-PARP domain (1024 to 1327 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation preincubated for 10 mins followed by biotinylated-N2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589519Effect on hippo signaling protein in human COLO320DM cells assessed as change in CTGF expression at 0.1 to 1 uM measured after 48 hrs by RT-PCR analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728587Half life in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548035Antiproliferative activity against human COLO320DM cells assessed inhibition of cell growth measured after 5 days by MTT assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548012Stability in mouse liver microsomes assessed as parent compound remaining at 1 uM measured after 60 mins in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589491Protein binding in mouse serum assessed as unbound fraction at 1 uM measured after 24 hrs by LC-MS/MS analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1548049Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548017Protein binding in human plasma assessed as unbound fraction at 1 uM measured after 24 hrs by LC-MS/MS analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728580Tmax in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728592Inhibition of TNKS1/2 in HEK293 cells assessed as inhibition of Wnt/beta-casein pathway after 24 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728465Bioavailability in female ICR mouse measured from AUC (0 to t) at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728566AUC (0 to t) in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548020Efflux ratio of permeability across basolateral to apical side over apical to basolateral side in MDCK2 cells2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728572Cmax in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728469Mean residence time (0 to infinity) in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589483Inhibition of recombinant human N-terminal TEV cleavage site-fused/FLAG-poly his-tagged TNKS2 SAM-PARP domain (613 to 1166 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation preincubated for 10 mins followed by biotinylated-N2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589484Inhibition of recombinant human PARP1 expressed in Escherichia coli assessed as reduction in auto-PARylation using histone as substrate measured after 45 mins in presence of biotinylated-NAD+ by ELISA2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728460Inhibition of PARP1 (unknown origin) up to 20 uM by NAD+-dependent autopoly(ADP ribosyl)lation assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1866944Toxicity in mouse xenografted with COLO 320DM cells assessed as reduction in body weight at 30 mg/kg, ip daily relative to control2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Small-Molecule Inhibitors of Tankyrases as Prospective Therapeutics for Cancer.
AID728577Tmax in female ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728556Clearance in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728576Cmax in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728588Half life in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589488Aqueous solubility of the compound in pH 7.4 phosphate buffer at 200 uM incubated for 1 hr under shaking condition by UV spectra analysis2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589525Antitumor activity against human COLO320DM cells xenografted in mouse assessed as tumor growth inhibition at 40 mg/kg, ip administered twice daily for 11 days relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589505Total clearance in Sprague-Dawley rat at 1 mg/kg, iv2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID1589509AUC (infinity) in Sprague-Dawley rat at 3 mg/kg, po2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728553Mean residence time (0 to infinity) in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548091Inhibition of TNKS/TNKS2-mediated WNT/beta-catenin signaling pathway in human COLO320DM cells assessed as reduction in active beta-catenin expression by measuring beta-catenin level at 0.1 uM measured after 16 hrs by Western blot analysis relative to GADP2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728467Oral bioavailability in female ICR mouse measured from AUC (0 to t) at 5 mg/kg2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728471Mean residence time (0 to infinity) in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728571AUC (0 to t) in male ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728590Inhibition of TNKS2 (unknown origin) by NAD+-dependent autopoly(ADP ribosyl)lation assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728569AUC (0 to t) in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548048Total clearance in Sprague-Dawley rat at 1 mg/kg, iv2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1589487Inhibition of TNKS/TNKS2 in human COLO320DM cells assessed as upregulation of AXIN2 expression at 0.33 uM measured after 16 hrs by Western blot analysis relative to G007-LK2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728579Tmax in female ICR mouse at 5 mg/kg, po2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548016Stability in human liver microsomes assessed as parent compound remaining at 1 uM measured after 60 mins in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548008Antiproliferative activity against human COLO320DM cells assessed as inhibition of cell growth measured after 4 days by CellTiter-Glo assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728455Inhibition of CYP3A4 (unknown origin)2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID728568AUC (0 to t) in male ICR mouse at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548046Oral bioavailability in Sprague-Dawley rat at 3 mg/kg2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548045AUC (infinity) in Sprague-Dawley rat at 3 mg/kg, po2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID728581Tmax in female ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589510Oral bioavailability in Sprague-Dawley rat at 3 mg/kg2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728461Bioavailability in female ICR mouse measured from AUC (0 to infinity) at 5 mg/kg, ip2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1589485Inhibition of TNKS/TNKS2 (unknown origin) expressed in human DLD1 cells assessed as reduction in Wnt-signaling measured after 24 hrs by TCF-luciferase reporter gene assay2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
AID728554Mean residence time (0 to infinity) in male ICR mouse at 1 mg/kg, iv2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1548038Dose normalized initial plasma concentration in Sprague-Dawley rat at 1 mg/kg, iv2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1548005Inhibition of recombinant human N-terminal TEV cleavage site-fused/FLAG-poly his-tagged TNKS2 ARC5-SAM-PARP domain (613 to 1166 residues) expressed in Escherichia coli assessed as reduction in auto-PARylation preincubated for 10 mins followed by biotinyla2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (57.69)24.3611
2020's11 (42.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.86 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]